DoW Breast Cancer, Breakthrough Award Levels 1 and 2 | HT942526BCRPBTA12

Opportunity Information: Apply for HT942526BCRPBTA12

The FY26 Department of Defense Breast Cancer Research Program (BCRP) Breakthrough Award Levels 1 and 2 grant opportunity is aimed at supporting breast cancer research that is both highly promising and positioned to produce a real "breakthrough" rather than incremental progress. The program is explicitly framed around making major advances with clear potential for meaningful impact in breast cancer, particularly work that can move the field forward toward clinical application. A key requirement is that every application must directly address at least one of the FY26 BCRP overarching challenges; if an applicant proposes work outside those challenges, they must provide a strong justification for why an exception is warranted. Importantly, it is not enough to mention a challenge in passing. The proposed research needs to tackle the chosen challenge in a way that plausibly leads to a breakthrough outcome and a major impact on breast cancer prevention, detection, prognosis, treatment, survivorship, or related areas, depending on what the FY26 challenges encompass in the full announcement materials.

This opportunity covers two of the four Breakthrough Award funding levels available under the broader Breakthrough Award mechanism. Each funding level is meant to support a different stage or scope of research on the pathway to clinical application, recognizing that different projects may be at different points in maturity. In this specific announcement, applicants can apply under Funding Level 1 or Funding Level 2. While the provided summary does not list the exact dollar caps for these levels, the structure signals that Level 1 and Level 2 are distinct in expectations, scope, and possibly readiness for translation. In other words, applicants are expected to select the level that matches the scale and ambition of their proposed work, and to design a project that fits the intent of that level rather than trying to force an overly broad or mismatched concept into the mechanism.

A notable feature of Funding Level 2 is an explicit option for Population Science Studies. This matters for applicants working in epidemiology, outcomes research, health services research, implementation science, disparities research, or other population-level approaches that can produce actionable insights at scale. The announcement indicates that, with compelling justification, population science studies may be able to request higher levels of funding and an additional year of performance. That flexibility suggests the program recognizes that some population-based projects require larger datasets, longer follow-up, broader recruitment, or more complex analytic and operational timelines than many lab-based or early translational studies.

The program also offers flexibility in leadership structure. Applications may be submitted by a single Principal Investigator (PI) or through a Partnering PI Option that involves two investigators: an Initiating PI and a Partnering PI. The coordination rules for the partnering approach are important because they affect how submissions are handled. Under the Partnering PI Option, only the Initiating PI submits the pre-application, but at the full application stage both the Initiating PI and the Partnering PI must submit their associated application materials. The notice is blunt about the consequence of missed coordination: if all required associated submissions are not received by the deadline, the application package may be administratively withdrawn. For teams considering the partnering route, that means the collaboration needs to be planned early, with clear responsibilities and internal deadlines to avoid a preventable disqualification.

From an administrative standpoint, this is a discretionary grant opportunity managed by the Department of the Army through the U.S. Army Medical Research Acquisition Activity (USAMRAA), categorized under science and technology research and development (CFDA 12.420). Eligibility is listed as unrestricted, which generally suggests a broad range of applicant organizations may apply (subject to the standard federal and program-specific requirements described in the full funding announcement). The opportunity number is HT942526BCRPBTA12, the original closing date is July 8, 2026, and the program anticipates making about 18 awards. The award ceiling is not stated in the provided text, so applicants would need to consult the full announcement to confirm the maximum allowable budget by funding level and any special cost constraints, including the conditions under which Level 2 population science projects may seek additional funding or time.

Overall, the takeaway is that this funding opportunity is designed for ambitious breast cancer research that is clearly aligned to defined program challenges and has a credible pathway to major advances. It supports either a single-PI approach or a structured two-PI partnership, and it carves out an explicit lane within Level 2 for population science work that may need extra resources or time when well justified.

• The Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoW Breast Cancer, Breakthrough Award Levels 1 and 2" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on 2026-05-04.
• Applicants must submit their applications by 2026-07-08. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 18 candidate(s).
• Eligible applicants include: Unrestricted.

Apply for HT942526BCRPBTA12

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: